Previous close | 13.18 |
Open | 13.18 |
Bid | 0.00 |
Ask | 0.00 |
Strike | 70.00 |
Expiry date | 2024-09-20 |
Day's range | 13.18 - 13.18 |
Contract range | N/A |
Volume | |
Open interest | N/A |
Axsome's (AXSM) bottom line declines year over year in the first quarter. Strong sales of Auvelity drive revenues.
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Q1 2024 Earnings Call Transcript May 6, 2024 Axsome Therapeutics, Inc. misses on earnings expectations. Reported EPS is $-1.44233 EPS, expectations were $-1.2. Axsome Therapeutics, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good morning, […]
Discover how Axsome Therapeutics achieved a 160% revenue increase and navigated heightened R&D and operational costs in Q1 2024.